Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Total Assets
Latest total assets as of June 2025: CN¥3.87 Billion CNY
Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) holds total assets worth CN¥3.87 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total assets of CN¥3.87 Billion consist of 41.5% current assets and 58.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.5% |
| Accounts Receivable | CN¥361.49 Million | 9.7% |
| Inventory | CN¥177.34 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥93.43 Million | 2.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s current assets represent 41.5% of total assets in 2024, a decrease from 61.5% in 2019.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, down from 49.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 15.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 9.7% of total assets.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Total Assets
Key competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is currently not profitable relative to its asset base.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 1.84 | 13.54 |
| Quick Ratio | 1.60 | 1.68 | 13.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥780.78 Million | CN¥ 792.99 Million | CN¥ 1.75 Billion |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.05 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 1.4% |
| Total Assets | CN¥3.72 Billion |
| Market Capitalization | $407.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s assets grew by 1.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2024)
The table below shows the annual total assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.72 Billion | +1.42% |
| 2023-12-31 | CN¥3.67 Billion | +25.24% |
| 2022-12-31 | CN¥2.93 Billion | +0.17% |
| 2021-12-31 | CN¥2.92 Billion | +344.01% |
| 2020-12-31 | CN¥658.75 Million | +73.98% |
| 2019-12-31 | CN¥378.63 Million | -- |